Skip to main content
. Author manuscript; available in PMC: 2021 Apr 26.
Published in final edited form as: Cancer Res. 2018 Mar 27;78(13):3484–3496. doi: 10.1158/0008-5472.CAN-17-3454

Figure 2.

Figure 2.

DNA methylation is involved in the epigenetic silencing of P53RRA. A–C, Genomic DNA derived from human lung ADC (A) and SCC tissues (B), corresponding normal lung tissues, and HBE, A549, SPCA1, and H522 cells (C) was examined by bisulfite sequencing of the P53RRA promoter regions. D, Real-time RT-PCR analyses detecting the P53RRA levels in lung cancer cells after the treatment with 5-azacytidine for 72 hours. E and F, The P53RRA levels were detected in xenografts derived from H522 cells (E) and A549 cells either stably expressing LSH or with LSH depleted (F). G, The correlation between LSH and P53RRA in lung cancer tissues was analyzed. H, ChIP analysis was used to detect the presence of LSH in the promoter region of P53RRA using two primer sites. I and J, ChIP analysis for the detection of the presence H3K27Me3 (I) and H3K4Me3 (J) at the transcription start site of P53RRA using two separate primer sites. K, ChIP analysis for the detection of Cfp1 binding to the promoter region of P53RRA using two primer sites. *, P < 0.05; **, P < 0.01; ***, P < 0.001.